Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ADA | P00813 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21124173 | 0.93 | TSHR (0.44) | TSHRGRM2CA2CPN1CPB2 | |
| SCHEMBL14465479 | 0.86 | CPN1 (0.41) | TSHRCA2CPN1CPB2 | |
| SCHEMBL9255104 | 0.86 | CPN1 (0.41) | TSHRCA2CPN1CPB2 | |
| SCHEMBL24349584 | 0.85 | TSHR (0.50) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL28300830 | 0.85 | TSHR (0.50) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL1068393 | 0.85 | TSHR (0.50) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL18557410 | 0.85 | TSHR (0.50) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL18896281 | 0.83 | TSHR (0.49) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL27560305 | 0.83 | TSHR (0.49) | TSHRCSNK1ESPHK1GRM2CNR1 | |
| SCHEMBL24767617 | 0.83 | TSHR (0.49) | TSHRCSNK1ESPHK1GRM2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | claimed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | claimed |
| CN-113663077-B | Wound healing via autologous stem cell mobilization | 美德睿臻有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-113663077-A | Wound healing via autologous stem cell mobilization | 美德睿臻有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-105658217-B | Wound healing via autologous stem cell mobilization | 约翰霍普金斯大学 | 2021-03-19 | — | — | CN | disclosed |
| US-10266491-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2720690-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | Children's Medical Center Corporation (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2694037-A1 | FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL]PROPANE -1, 3 - DIOL | Novartis AG (CH) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012174522-A1 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266491-B2 | Carbazole derivatives | BTK, SYK, JAK2 | TSHR 1190/4885CSNK1E 59/4885SPHK1 956/4885 |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | TSHR 1190/4885CSNK1E 59/4885SPHK1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.